CA-QUECTEL-WIRELESS
3.1.2023 10:01:41 CET | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, has announced the launch of the latest addition to its LTE module portfolio, the industrial grade EG800Q-EU LTE Cat.1 bis wireless communication module. An ultra-compact module in LGA form factor, the EG800Q-EU offers greater flexibility in IoT designs and enables a wider range of IoT use cases, particularly for size sensitive applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230103005121/en/
EG800Q-EU - ultra-compact, high-performance Cat.1 bis solution (Graphic: Business Wire)
Based upon the Qualcomm® QCX216 LTE IoT Modem from Qualcomm Technologies Inc., the EG800Q-EU is an LTE only module for customers in Europe, the Middle East, Africa, Australia, New Zealand, and Israel markets with LTE FDD band coverage of B1/ 3/ 5/ 7/ 8/ 20/ 28. The module delivers a maximum downlink data rate of 10 Mbps while enhancing battery life, critical for a variety of high-performing IoT applications including smart utility meters, asset trackers, e-mobility, parking meters, and home automation.
The EG800Q-EU’s support of Cat.1 bis allows it to use a single antenna, balancing cost and performance and making the module an ideal solution for IoT terminals that are designed to be compact and cost-effective.
“We feel very excited that our EG800Q-EU is one of the industry’s first Cat.1 modules based on the Qualcomm QCX216 LTE IoT Modem, a cost-optimized, power efficient global Cat.1 bis modem,” said Norbert Muhrer, President and CSO of Quectel. “The module’s unrivalled advantages make it ideal for a multitude of mid-range use cases and deployment scenarios which demand reliable and cost-effective communication solutions.”
The EG800Q-EU has a compact form factor of 15.8mm × 17.7mm × 2.4mm, enabling integrators and developers to design size sensitive applications easily. Its advanced LGA package enables fully automated manufacturing for high-volume applications.
The EG800Q-EU also provides a rich set of Internet protocols, and industry-standard interfaces including USB 2.0/ UART/ I2C/ PCM/ USIM, extending the suitability of the module to a variety of IoT applications such as asset management, remotely managed access control (RMAC), and smart grid. Additionally, the module supports DFOTA to enable automatic firmware upgrade and integrated Wi-Fi positioning services when there is no GPS signal indoors.
To help customers to facilitate their designs, Quectel offers a variety of high-performance LTE Cat.1 antennas which boost wireless connectivity significantly. IoT developers can bundle the EG800Q-EU module with Quectel’s antennas and pre-certification services, reducing both cost and time-to-market for their Cat.1 devices.
Engineering samples of the Quectel EG800Q-EU are available now.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated.
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005121/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom